1. Baudouin C. The pathology of dry eye.
Surv Ophthalmol 2001;45:S211-S220.
2. Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes.
CLAO J 1995;21:221-232.
3. Yeh S, Song XJ, Farley W, et al. Apoptosis of ocular surface cells in experimentally induced dry eye.
Invest Ophthalmol Vis Sci 2003;44:124-129.
4. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine.
Arch Ophthalmol 2002;120:330-337.
5. Turner K, Pflugfelder SC, Ji Z, et al. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion.
Cornea 2000;19:492-496.
6. Pflugfelder SC, Tseng SC, Yoshino K, et al. Correlation of goblet cell density and mucosal epithelial membrane mucin expression with rose bengal staining in patients with ocular irritation.
Ophthalmology 1997;104:223-235.
7. Baudouin C, Brignole F, Becquet F, et al. Flow cytometry in impression cytology specimens: a new method for evaluation of conjunctival inflammation. Invest Ophthalmol Vis Sci 1997;8:1458-1464.
8. Brignole F, Pisella PJ, Dupas B, et al. Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis.
Graefes Arch Clin Exp Ophthalmol 2005;243:531-538.
9. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease.
Ophthalmology 2000;107:631-639.
10. Tatlipinar S, Akpek EK. Topical ciclosporin in the treatment of ocular surface disorders.
Br J Ophthalmol 2005;89:1363-1367.
11. Papa V, Aragona P, Russo S, et al. Comparison of hypotonic and isotonic solutions containing sodium hyaluronate on the symptomatic treatment of dry eye patients.
Ophthalmologica 2001;215:124-127.
12. Nepp J, Schauersberger J, Schild G, et al. The clinical use of viscoelastic artificial tears and sodium chloride in dry-eye syndrome.
Biomaterials 2001;22:3305-3310.
13. Campo GM, Avenoso A, Campo S, et al. Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats.
Arthritis Res Ther 2003;5:R122-R131.
14. Hamano H, Hori M, Hamano T, et al. A new method for measuring tears.
CLAO J 1983;9:281-289.
15. Toda I, Tsubota K. Practical double vital staining for ocular surface evaluation.
Cornea 1993;12:366-367.
16. Saini JS, Rajwanshi A, Dhar S. Clinicopathological correlation of hard contact lens related changes in tarsal conjunctiva by impression cytology.
Acta Ophthalmol(Copenh) 1990;68:65-70.
17. Kinoshita S, Kiorpes TC, Friend J, Thoft RA. Goblet cell density in ocular surface disease. A better indicator than tear mucin.
Arch Ophthalmol 1983;101:1284-1287.
18. Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
Ophthalmology 2005;112:1790-1794.
19. Strong B, Farley W, Stern ME, Pflugfelder SC. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca.
Cornea 2005;24:80-85.
20. Moore CP, McHugh JB, Thorne JG, Phillips TE. Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model.
Invest Ophthalmol Vis Sci 2001;42:653-659.
21. el Tayar N, Mark AE, Vallat P, et al. Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations.
J Med Chem 1993;36:3757-3764.
22. Mithani SD, Bakatselou V, TenHoor CN, Dressman JB. Estimation of the increase in solubility of drugs as a function of bile salt concentration.
Pharm Res 1996;13:163-167.
23. Kuwano M, Ibuki H, Morikawa N, et al. Cyclosporine A formulation affects its ocular distribution in rabbits.
Pharm Res 2002;19:108-111.
24. Limberg MB, McCaa C, Kissling GE, Kaufman HE. Topical application of hyaluronic acid and chondroitin sulfate in the treatment of dry eyes.
Am J Ophthalmol 1987;103:194-197.
25. Shimmura S, Ono M, Shinozaki K, et al. Sodium hyaluronate eyedrops in the treatment of dry eyes.
Br J Ophthalmol 1995;79:1007-1011.
26. Fukuda K, Miyamoto Y, Miyara Y. Hyaluronic acid in tear fluid and its synthesis by corneal epithelial cells. Asia-pacific J Ophthalmo 1998;40:62-65.
27. Inoue M, Katakami C. The effect of hyaluronic acid on corneal epithelial cell proliferation.
Invest Ophthalmol Vis Sci 1993;34:2313-2315.
28. Nishida T, Nakamura M, Mishima H, Otori T. Hyaluronan stimulates corneal epithelial migration.
Exp Eye Res 1991;53:753-758.
29. Lerner LE, Schawrtz DM, Hwang DG, et al. Hyaluronan and CD44 in the human cornea and limbal conjunctiva.
Exp Eye Res 1998;67:481-484.
30. Entwistle J, Hall CL, Turley EA. HA receptors: signalling to the cytoskeleton.
J Cell Biochem 1996;61:569-577.
31. Rosales C, O'Brien V, Kornberg L, Juliano R. Signal transduction by cell adhesion receptors.
Biochem Biophys Acta 1995;1242:77-98.
32. Miyazaki T, Miyauchi S, Nakamura T, et al. The effect of sodium hyaluronate on the growth of rabbit corneal epithelial cells in vitro.
J Ocul Pharmacol Ther 1996;12:409-415.
33. Nakamura M, Hikida M, Nakano T, et al. Characterization of water retentive properties of hyaluronan.
Cornea 1993;12:433-436.
34. Nelson JD, Farris RL. Sodium hyaluronate and polyvinyl alcohol artificial tear preparations. A comparison in patients with keratoconjunctivitis sicca.
Arch Ophthalmol 1988;106:484-487.
35. Stadler J, Stefanovic-Racic M, Billiar TR, et al. Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharide.
J Immunol 1991;147:3915-3920.
36. Solomon A, Dursun D, Liu Z, et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease.
Invest Ophthalmol Vis Sci 2001;42:2283-2292.
37. Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface.
Invest Ophthalmol Vis Sci 2004;45:4293-4301.